Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Exocrine function reduced in all patients (n = 10) following SSA therapy (median reduction from baseline: −23.4% (range: −42.1 to 0.5%, p = 0.005)). vitamin D levels decreased in all but one patient (median decrease from baseline: −26.5%, (−44.7 to 10%; p = 0.038)), and median HbA1C levels increased by 8.0% (0 to 59.3%; p = 0.008).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Healthy volunteers were age: and sex-matched to the included patients and used as controls.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?

Study design awaiting verification · Cancers · 2023

Original publication title

Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?

Lewis A. Hall; Sarah Powell-Brett; Oscar Thompson; Daniel Smith; Elizabeth Bradley; Stacey Smith; Suzanne Vickrage; Joanne Kemp-Blake; Keith J. Roberts; Tahir Shah

© 2023 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: Simple Summary

Somatostatin analogues (SSA) are used to treat patients with unresectable neuroendocrine tumours (NET). An underrecognized side-effect of SSAs is pancreatic exocrine insufficiency (PEI), where the pancreas is unable to maintain the normal digestion of food. Whilst the few papers that have investigated SSA-induced PEI report rates of between 12 and 48%, anecdotal evidence of PEI symptoms suggests this figure is greater. The disparity may be due to the overlap in symptoms of the tumour itself and PEI, but also the diagnostic methods used.

Swift diagnosis of PEI is essential to ensure appropriate management of the symptoms for an improved survival and quality of life for patients. This study is the first to utilize the 13C-mixed triglyceride breath test (13C-MTGT) in patients before and after they commence SSA treatment, demonstrating a novel and alternative diagnostic strategy in this patient cohort, whilst highlighting the early impact of SSAs on pancreatic function.

Source: Simple Summary

Abstract: Abstract

Somatostatin-analogues (SSAs) are a first-line treatment of unresectable neuroendocrine tumours (NETs). However, SSAs inhibit pancreatic secretions, which could lead to pancreatic exocrine insufficiency (PEI). PEI is known to be detrimental to patient quality of life and nutritional status. This study aimed to evaluate the effect of SSAs on pancreatic exocrine function in patients with NETs, using the 13C-mixed triglyceride breath test (13C-MTGT). Exocrine function was assessed using the 13C-MTGT at baseline and after a third SSA injection (two months).

A quotient of 13CO2/12CO2 was measured by mass spectrometry, and the cumulative percent dose recovered at 6 h (cPDR) is reported. The secondary endpoints investigated were change in weight, HbA1C, and vitamin D levels. Ten patients completed the study. Exocrine function reduced in all patients (n = 10) following SSA therapy (median reduction from baseline: −23.4% (range: −42.1 to 0.5%, p = 0.005)). vitamin D levels decreased in all but one patient (median decrease from baseline: −26.5%, (−44.7 to 10%; p = 0.038)), and median HbA1C levels increased by 8.0% (0 to 59.3%; p = 0.008).

Change in weight was not significant (median decrease from baseline: −0.21% (−4.5 to 3.5%, p = 1.000)). SSA therapy has a consistent impact on exocrine function from early in the treatment course, but the long-term clinical effects of this remain to be defined. Further studies are required to determine the clinical relevance of this observation and optimise the management of PEI in this cohort.

Source: Abstract
Authors’ abstract

Simple Summary

Somatostatin analogues (SSA) are used to treat patients with unresectable neuroendocrine tumours (NET). An underrecognized side-effect of SSAs is pancreatic exocrine insufficiency (PEI), where the pancreas is unable to maintain the normal digestion of food. Whilst the few papers that have investigated SSA-induced PEI report rates of between 12 and 48%, anecdotal evidence of PEI symptoms suggests this figure is greater. The disparity may be due to the overlap in symptoms of the tumour itself and PEI, but also the diagnostic methods used.

Swift diagnosis of PEI is essential to ensure appropriate management of the symptoms for an improved survival and quality of life for patients. This study is the first to utilize the 13C-mixed triglyceride breath test (13C-MTGT) in patients before and after they commence SSA treatment, demonstrating a novel and alternative diagnostic strategy in this patient cohort, whilst highlighting the early impact of SSAs on pancreatic function.

Abstract

Somatostatin-analogues (SSAs) are a first-line treatment of unresectable neuroendocrine tumours (NETs). However, SSAs inhibit pancreatic secretions, which could lead to pancreatic exocrine insufficiency (PEI). PEI is known to be detrimental to patient quality of life and nutritional status. This study aimed to evaluate the effect of SSAs on pancreatic exocrine function in patients with NETs, using the 13C-mixed triglyceride breath test (13C-MTGT). Exocrine function was assessed using the 13C-MTGT at baseline and after a third SSA injection (two months).

A quotient of 13CO2/12CO2 was measured by mass spectrometry, and the cumulative percent dose recovered at 6 h (cPDR) is reported. The secondary endpoints investigated were change in weight, HbA1C, and vitamin D levels. Ten patients completed the study. Exocrine function reduced in all patients (n = 10) following SSA therapy (median reduction from baseline: −23.4% (range: −42.1 to 0.5%, p = 0.005)). vitamin D levels decreased in all but one patient (median decrease from baseline: −26.5%, (−44.7 to 10%; p = 0.038)), and median HbA1C levels increased by 8.0% (0 to 59.3%; p = 0.008).

Change in weight was not significant (median decrease from baseline: −0.21% (−4.5 to 3.5%, p = 1.000)). SSA therapy has a consistent impact on exocrine function from early in the treatment course, but the long-term clinical effects of this remain to be defined. Further studies are required to determine the clinical relevance of this observation and optimise the management of PEI in this cohort.

Publication and source details

Original title: Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?

Lewis A. Hall; Sarah Powell-Brett; Oscar Thompson; Daniel Smith; Elizabeth Bradley; Stacey Smith; Suzanne Vickrage; Joanne Kemp-Blake; Keith J. Roberts; Tahir Shah

Cancers · 2023

* Correspondence: keith.roberts@uhb.nhs.uk© 2023 by the authors.2023https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).This research received no external funding from any agency in the public, commercial, or not-for-profit sectors.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T07:30:49.653031+00:00

DOI: 10.3390/cancers15071933 · PMC10093494